India bolsters regulators to brace global competition
India is bolstering its regulatory bodies to global standards to become a world leader in drug discovery and innovative medical devices, a minister.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
India is bolstering its regulatory bodies to global standards to become a world leader in drug discovery and innovative medical devices, a minister.
Glenmark Pharmaceuticals, an Indian multinational firm, has introduced its heart failure drug in the country, according to a company statement.
Pharma major Lupin has received a ‘tentative approval’, from the United States Food and Drug Administration (FDA), to market medicines used to treat.
The USFDA has granted Zydus Lifesciences Limited ‘tentative approval’ to market Levomilnacipran extended-release capsules in 20 mg, 40 mg, 80 mg, and 120.
The Indian pharmaceutical industry is expected to witness “decent growth” during the three-month period through 31 March 2023, mainly led by continued traction.
Eiasi Co., a Japanese pharmaceutical company, has submitted a marketing authorization application for a drug, lacanemab, to treat Alzheimer's disease.
he current treatment of cortical malformations in the anterior parts of the brain, or cerebrum, in vertebrates by its surgical removal to cure.
China has provided the WHO with information about its outpatient clinics, hospitalizations, patients requiring emergency treatment and hospital deaths due to Coivd-19 infection,.
An artificial intelligence-powered machine can reduce the treatment time for stroke patients by 60 minutes and free up clinicians’ time.
The WHO has issued a Medical Product Alert on India’s Marion Biotech’s Ambronol and DOK-1 Max syrups as they failed to meet quality.